Sign In
Buy HOTH
$1.36
+0 (+0%)
At Close: Jun 03, 2026
Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial
09:15am, Monday, 12'th Apr 2021
NEW YORK, April 12, 2021 /PRNewswire/ -- Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, together with its manufacturing partner, has successfully complet
NEW YORK, April 6, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced that it has engaged Worldwide Clinical Trials ("Worldwide"), a
NEW YORK, April 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that the Brazilian Patent Office has issue
Hoth Therapeutics' Partner Voltron Therapeutics Reports Encouraging Preclinical Data From COVID-19 Vaccine Candidate
10:26am, Wednesday, 24'th Mar 2021
Hoth Therapeutics Inc's (NASDAQ: HOTH) development partner, Voltron Therapeutics Inc has announced positive data from its second set of preclinical animal testing of HaloVax Self-Assembling Vaccin
HOTH Stock: The News That Has Biopharma Hoth Therapeutics Shooting Higher Today
11:45am, Tuesday, 23'rd Mar 2021
Shares of HOTH stock are blasting off on Tuesday morning after strong preclinical results from the firm's coronavirus treatment. The post HOTH Stock: The News That Has Biopharma Hoth Therapeutics Shoo
HOTH Stock Price Increases Over 40% Pre-Market: Why It Happened
08:25am, Tuesday, 23'rd Mar 2021
The stock price of Hoth Therapeutics Inc (NASDAQ: HOTH) has increased by over 40% pre-market. This is why it happened.
Hoth Therapeutics Announces Positive Preclinical Results for Novel COVID-19 Therapeutic
08:01am, Tuesday, 23'rd Mar 2021
NEW YORK, March 23, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating SARS-CoV-2 antiviral activity for its
Hoth Therapeutics CEO, Robb Knie, Featured on the RedChip Money Report on Bloomberg TV this Saturday, March 20th
07:00am, Friday, 19'th Mar 2021
NEW YORK, March 19, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced an exclusive interview featuring Robb Knie
Hoth Therapeutics Inks Research Pact For Critical Studies Of HT-006 Antibiotic
02:20pm, Wednesday, 17'th Mar 2021
Hoth Therapeutics Inc (NASDAQ: HOTH) has entered into a Research Agreement with the University of Cincinnati Research Institute to perform critical antimicrobial characterization studies with HT-0
Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006
01:24pm, Wednesday, 17'th Mar 2021
NEW YORK, March 17, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a Research Agreement with the University of Cincinnati
Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease
09:15am, Thursday, 11'th Mar 2021
NEW YORK, March 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed an agreement with REPROCELL Ltd., a contract research
Hoth Therapeutics Completes Closing of Previously Announced $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
03:50pm, Wednesday, 10'th Mar 2021
NEW YORK, March 10, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today announced the closing of its previously announced p
Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules
05:00pm, Monday, 08'th Mar 2021
NEW YORK, March 8, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today announced that it has entered into a definitive agreem
Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies
08:01am, Wednesday, 03'rd Mar 2021
NEW YORK, March 3, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today provided an update on preclinical study on HT-002 for
NEW YORK, March 1, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, is pleased to announce it has completed recruitment of Cohort 1 for its upcoming first in h
